Overview
ANRO market data
Price History
ANRO price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for ANRO. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
8-K filing — Alto Neuroscience, Inc. (ANRO)SEC EDGAR · Jul 14, 2026, 10:04 AM
Alto Neuroscience Prices ~$100M Offering Of 3.776M Common Shares At $26.48/ShareBenzinga · Jul 13, 2026, 11:48 AM
Alto Neuroscience Intends To Accelerate And Expand Clinical Development Of ALTO-207, Including An Additional Planned Phase 3 Trial As Monotherapy For Treatment-Resistant DepressionBenzinga · Jul 13, 2026, 11:46 AM
Alto Neuroscience Publishes Trial Of Dopamine Agonist Pramipexole With Mood Disorders And Clinically Significant Anhedonia In Nature MediceBenzinga · Jun 15, 2026, 12:20 PM
Baird Maintains Outperform on Alto Neuroscience, Lowers Price Target to $36Benzinga · May 18, 2026, 5:10 PM
Wedbush Maintains Neutral on Alto Neuroscience, Raises Price Target to $24Benzinga · May 14, 2026, 1:06 PM
Alto Neuroscience Q1 EPS $(0.80) Misses $(0.54) EstimateBenzinga · May 13, 2026, 11:25 AM